THE CORRELATION OF KI67 GROWTH-FACTOR AND ERICA IN BREAST-CANCER

被引:0
作者
HANNA, WM [1 ]
KAHN, HJ [1 ]
CHAPMAN, JAW [1 ]
机构
[1] UNIV TORONTO,WOMENS COLL HOSP,HENRIETTA BANTING BREAST CTR,TORONTO M5S 1B2,ONTARIO,CANADA
关键词
ERICA; KI67; BREAST CANCER; PROGNOSTIC FACTORS;
D O I
暂无
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
Estrogen receptor (ER) status is an accepted prognostic indicator for breast cancer when measured by either the biochemical or immunohistochemical (ERICA) methods. Moreover, ERICA was found to be a better predictor of survival in human breast cancer than the biochemical assay for ER. The antibody to Ki67 recognizes the growth fraction of proliferating cells. We examined 100 primary breast cancers to investigate the relationship between ER status as measured by ERICA and Ki67 reactivity. Of the 56 ERICA positive cases, 47 (84%) were Ki67 negative whereas 30 of the 44 ERICA negative tumors were Ki67 positive (68%). There was evidence of a significant inverse relationship between ERICA and the growth fraction (77% of cases, p < 0.001). In addition, a cluster of ERICA-positive Ki67-positive tumors that were larger and occurred in older patients was identified as a subset that might require aggressive therapy. Our results suggest that Ki67 may be an important additional criterion for predicting the biological behaviour of breast cancers.
引用
收藏
页码:220 / 223
页数:4
相关论文
共 28 条
[1]  
BACUS SS, 1989, AM J PATHOL, V135, P783
[2]   THE USE OF THE MONOCLONAL-ANTIBODY KI-67 IN THE IDENTIFICATION OF PROLIFERATING CELLS - APPLICATION TO SURGICAL NEUROPATHOLOGY [J].
BURGER, PC ;
SHIBATA, T ;
KLEIHUES, P .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 1986, 10 (09) :611-617
[3]   IMMUNOHISTOLOGICAL DETERMINATION OF PROLIFERATIVE ACTIVITY IN SEMINOMAS [J].
DUE, W ;
DIECKMANN, KP ;
LOY, V .
JOURNAL OF CLINICAL PATHOLOGY, 1988, 41 (03) :304-307
[4]   A RANDOMIZED CLINICAL-TRIAL EVALUATING SEQUENTIAL METHOTREXATE AND FLUOROURACIL IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR-NEGATIVE TUMORS [J].
FISHER, B ;
REDMOND, C ;
DIMITROV, NV ;
BOWMAN, D ;
LEGAULTPOISSON, S ;
WICKERHAM, DL ;
WOLMARK, N ;
FISHER, ER ;
MARGOLESE, R ;
SUTHERLAND, C ;
GLASS, A ;
FOSTER, R ;
CAPLAN, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :473-478
[5]   10-YEAR RESULTS OF A RANDOMIZED CLINICAL-TRIAL COMPARING RADICAL MASTECTOMY AND TOTAL MASTECTOMY WITH OR WITHOUT RADIATION [J].
FISHER, B ;
REDMOND, C ;
FISHER, ER ;
BAUER, M ;
WOLMARK, N ;
WICKERHAM, DL ;
DEUTSCH, M ;
MONTAGUE, E ;
MARGOLESE, R ;
FOSTER, R .
NEW ENGLAND JOURNAL OF MEDICINE, 1985, 312 (11) :674-681
[6]   A RANDOMIZED CLINICAL-TRIAL EVALUATING TAMOXIFEN IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR POSITIVE TUMORS [J].
FISHER, B ;
COSTANTINO, J ;
REDMOND, C ;
POISSON, R ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
WOLMARK, N ;
WICKERHAM, DL ;
FISHER, ER ;
MARGOLESE, R ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J ;
PATERSON, AHG ;
FELDMAN, MI ;
FARRAR, W ;
EVANS, J ;
LICKLEY, HL ;
KETNER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :479-484
[7]   RELATIVE WORTH OF ESTROGEN OR PROGESTERONE-RECEPTOR AND PATHOLOGIC CHARACTERISTICS OF DIFFERENTIATION AS INDICATORS OF PROGNOSIS IN NODE NEGATIVE BREAST-CANCER PATIENTS - FINDINGS FROM NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT PROTOCOL B-06 [J].
FISHER, B ;
REDMOND, C ;
FISHER, ER ;
CAPLAN, R .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (07) :1076-1087
[8]  
GERDES J, 1984, J IMMUNOL, V133, P1710
[9]  
GROGAN TM, 1988, BLOOD, V71, P1157
[10]   COMPARATIVE-EVALUATION OF ER-ICA AND ENZYME-IMMUNOASSAY FOR THE QUANTITATION OF ESTROGEN-RECEPTORS IN BREAST-CANCER [J].
HANNA, W ;
MOBBS, BG .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 1989, 91 (02) :182-186